IMRALDI 40 mg, solution for injection in a pre-filled syringe syringe, 0.8 ml
Active ingredients: Adalimumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 0.8 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- IMRALDI 40 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 0,8 ml avec 2 tampon(s) alcoolisé(s)
- Marketing authorisation holder
- SAMSUNG BIOEPIS NL (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 7 Nov 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
61192750CIP73014371CIP133400930143711Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ADALIMUMABsolution | 40 mg · 0,8 ml de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.